Abstracts tagged "Systemic sclerosis"

Abstract Number: 1856 • ACR Convergence 2021
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
Ranjitha Karanth¹, Giuseppina Abignano², Vishal Kakkar², Rebecca Ross², Christopher Denton³ and Francesco Del Galdo², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, LTHT, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) carries a highly variable prognosis and to date there are no stratification tools to predict clinical outcomes. Evidence suggests…
Abstract Number: 0401 • ACR Convergence 2021
Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study
John Pauling¹, Lan Yu², Christopher Denton³, Tracy Frech⁴, Ariane Herrick⁵, Laura Hummers⁶, Lesley Ann Saketkoo⁷, Ami Shah⁸, Dinesh Khanna⁹ and Robyn Domsic², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Pittsburgh, Pittsburgh, PA, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁴University of Utah, Salt Lake City, UT, ⁵University of Manchester, Salford, United Kingdom, ⁶Johns Hopkins Univerisity, Baltimore, MD, ⁷University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome (PRO) instrument devised to assess the severity and impact of…
Abstract Number: 0547 • ACR Convergence 2021
Autologous Haematopoietic Stem Cell Transplantation for Systemic Sclerosis Results in Sustained Changes in Immunoregulatory T and NK Cells
Ross Penglase, Malini Visweswaran, John Zaunders, Laila Girgis, David Ma and John Moore, St Vincent's Hospital, Sydney, Australia
Background/Purpose: Autologous Haematopoietic Stem Cell Transplantation (AHSCT) is an effective treatment for severe systemic sclerosis (SSc). To date, mechanistic studies have indicated possible pro-regulatory and…
Abstract Number: 1001 • ACR Convergence 2021
Exosomes Mediate a Cooperative Mechanism of Macrophage/Fibroblast Activation in Systemic Sclerosis
Rajan Bhandari¹, Heetaek Yang², Noelle Kosarek³, Michael Whitfield⁴ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Geisel School of Medicine, Hanover, NH, ³Dartmouth Geisel School of Medicine, Hartford, VT, ⁴Geisel School of Medicine, Lebanon, NH
Background/Purpose: Prior work demonstrates that macrophages (MØs) from patients with Systemic Sclerosis (SSc) produce fibrotic and pro-inflammatory mediators and that cocultured MØs and SSc fibroblasts…
Abstract Number: 1375 • ACR Convergence 2021
Improvement in Overall Survival, Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis
Nancy Maltez¹, Mianbo Wang², Georges Wells³, Peter Tugwell¹, Murray Baron⁴, Zora Marjanovic⁵, Pauline Lansiaux⁶, Dominique Farge⁶ and Marie Hudson⁷, ¹The Ottawa Hospital, Ottawa, ON, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Jewish General Hospital, Montréal, QC, Canada, ⁵Hopital Saint-Antoine, Paris, France, ⁶8. Centre de Référence des Maladies auto-immunes systémiques Rares d’Ile-de-France, Paris, France, ⁷McGill University, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a chronic disease characterized by vasculopathy, inflammation and fibrosis. Rheumatologists have limited options to effectively treat rapidly progressive disease. There…
Abstract Number: 1838 • ACR Convergence 2021
Further Construct Validation of the
Julia Spierings¹, Voon Ong² and Christopher Denton³, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²University College London Medical School Royal Free Campus, London, United Kingdom, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Evaluation of skin is central in clinical management of systemic sclerosis (SSc). Due to the COVID-19 pandemic remote consultations were widely implemented, which inevitably…
Abstract Number: 1857 • ACR Convergence 2021
Ultra-High Frequency Ultrasound Compared to Durometry and Skin Score for Cutaneous Assessment in Systemic Sclerosis
Marco Di Battista¹, Saverio Vitali², Simone Barsotti³, Alessandra Della Rossa⁴, Valentina Dini⁵, Marco Romanelli⁵ and Marta Mosca³, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Radiology Unit - University of Pisa, Pisa, Italy, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁴Rheumatology Unit - University of Pisa, Pisa, Italy, ⁵Dermatology Unit - University of Pisa, Pisa, Italy
Background/Purpose: To assess skin involvement in a cohort of patients with systemic sclerosis (SSc) comparing results obtained from modified Rodnan skin score (mRSS), durometry and…
Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Alain Lescoat¹, Susan Murphy², Yen Chen³, Nadia Vann¹, David Cella⁴ and Dinesh Khanna³, ¹Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Michigan, Grosse Ile, MI, ³University of Michigan, Ann Arbor, MI, ⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
Abstract Number: 0549 • ACR Convergence 2021
Upregulation of Prostanoid EP2 Receptors and Meditation of Treprostinil Anti-Proliferative Effects in Scleroderma Smooth Muscle Cells
Yongqing Wang¹, Nezam Altorok² and Bashar Kahaleh², ¹University of Toledo Medical Center, Toledo, OH, ²University of Toledo, Toledo, OH
Background/Purpose: Progressive functional and structural vascular disorder is one of the hallmark features of Systemic Sclerosis (Scleroderma, SSc). Vascular dysfunction leads to dysregulated vascular tone…
Abstract Number: 1044 • ACR Convergence 2021
Older Patients with Rheumatic Disease Are Commonly Prescribed Potentially Inappropriate Medications
Christine Anastasiou, Michael Evans, Gabriela Schmajuk and Jinoos Yazdany, University of California San Francisco, San Francisco, CA
Background/Purpose: Reducing exposure to potentially inappropriate medications (PIMs) in older adults may minimize adverse drug events. The American Geriatrics Society (AGS) Beers Criteria® of Potentially…
Abstract Number: 1378 • ACR Convergence 2021
Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort
Matthew Kirkpatrick¹, Janet Lee¹, Anne Tebo², Haojia Li¹, yue zhang¹ and Tracy Frech¹, ¹University of Utah, Salt Lake City, UT, ²Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Autoantibodies are included in the disease classification criteria for systemic sclerosis (SSc). Our group previously reported the level of topoisomerase autoantibody as an important…
Abstract Number: 1839 • ACR Convergence 2021
Hispanic Patients with Systemic Sclerosis Have More Severe Disease and Higher Mortality: A Longitudinal Cohort Study
Bochra Jandali¹, Marka Lyons², Julio Charles², Maureen Mayes³ and Shervin Assassi¹, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, ³Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) shows disparities in incidence, disease manifestations, and prognosis in different ethnic groups. The data regarding disease characteristics and outcomes in Hispanic…
Abstract Number: 1860 • ACR Convergence 2021
Three Distinct Transcriptional Profiles of Monocytes Correlate with Disease Activity in SSc Patients
Hadijat Makinde¹, Gaurav Gadhvi¹, Salina Dominguez¹, Miranda Gurra¹, Kathleen Aren², Mary Carns², Tracy Frech³, Dinesh Khanna⁴, Shervin Assassi⁵, Lutfiyya Muhammad⁶, Carla Cuda¹, Monique Hinchcliff⁷, Deborah Winter² and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University Division of Rheumatology, Chicago, IL, ³University of Utah, Salt Lake City, UT, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Yale School of Medicine, Westport, CT
Background/Purpose: Patients with SSc display a complex clinical phenotype.Our group has made important contributions to an emerging understanding of monocytes and macrophages as central to…
Abstract Number: 0403 • ACR Convergence 2021
Effect of Nintedanib on KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
Shervin Assassi¹, Christopher Denton², Maurizio Cutolo³, Tracy Luckhardt⁴, Claudia Diefenbach⁵, Carina Ittrich⁶, Margarida Alves⁷ and Masataka Kuwana⁸, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ³Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ⁴University of Alabama, Birmingham, AL, ⁵Boehringer Ingelheim Pharma GmBH, Biberach an der Riss, Germany, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁸Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Krebs von den Lungen-6 (KL-6), a marker of lung epithelial and endothelial injury, has been associated with progression of interstitial lung disease associated with…
Abstract Number: 0550 • ACR Convergence 2021
Treatment Regimens and Outcomes in Systemic Sclerosis-associated Pulmonary Arterial Hypertension
Hilde Jenssen Bjørkekjær¹, Håvard Fretheim², Helene Marjavara Inselseth³, Øyvind Midtvedt⁴, Imon Barua⁴, Torhild Garen⁵, Helle Bitter¹, Arne Andreassen⁶, Øyvind Molberg⁴, Kaspar Broch⁶ and Anna-Maria Hoffmann-Vold⁴, ¹Department of Rheumatology, Sørlandet sykehus HF, Kristiansand, Norway, ²Oslo University Hospital, Oslo, Norway, ³University of Oslo, Oslo, Norway, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Nepal, ⁶Department of Cardiology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). It is associated with impaired quality of life and high mortality.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].